For example, Li et al. [24] demonstrated that blocking FcRL3 with specific monoclonal antibodies reduces B-cell activation in response to TLR9, lowering both proliferation and antibody production, and thereby suggesting potential clinical utility for controlling excessive humoral responses in RA. This evidence concerns the gene FCRL3 and rheumatoid arthritis.